Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial by Yanling Wu, Yuan Li, Ping Zhang, Siwei Guo, Fang Yuan, Vivian Liu, Ting Yu, Feng Lin, Nan Yang, Chao Tu, Hongzhou Lu, Tianlei Ying, Xin Li

Get full text